Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.
It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.
The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts.
The company is based in Redwood City, California.
Country | United States |
IPO Date | Jan 10, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 45 |
CEO | Ronald A. Martell |
Contact Details
Address: 2200 Bridge Pkwy Redwood City, California United States | |
Website | https://jaspertherapeutics.com |
Stock Details
Ticker Symbol | JSPR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001788028 |
CUSIP Number | 471871103 |
ISIN Number | US4718712023 |
Employer ID | 84-2984849 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Ronald A. Martell | President, Chief Executive Officer & Director |
Herbert C. Cross CPA | Chief Financial Officer & Corporate Secretary |
Jeetinder Singh Mahal M.B.A. | Chief Operating Officer |
David Ku M.D. | Vice President of Corporate Development, Portfolio Strategy & Management |
Dr. Edwin Jonathan Tucker M.D. | Chief Medical Officer |
Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder & Director |
Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations |
Dr. Wendy Pang M.D., Ph.D. | Senior Vice President of Research & Translational Medicine |
Matthew Ford | Vice President of Human Resources |
Patricia Carlos | Senior Vice President of Regulatory Affairs & Quality |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 12, 2024 | 4 | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 07, 2024 | 8-K | Current Report |
Nov 07, 2024 | 10-Q | Quarterly Report |
Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Oct 15, 2024 | 8-K | Current Report |
Sep 12, 2024 | 4 | Filing |
Aug 13, 2024 | 10-Q | Quarterly Report |